Innate Pharma S.A. (NASDAQ:IPHA) Q4 2023 Earnings Call Transcript

Sonia Quaratino: Sure. Originally, we — when we had the data of Sézary, there was the option of going to the regulators with Sézary data alone, where we had a Fast Track Designation and PRIME. Now we can really plan to merge the data, as I said, to maximize the value of lacutamab not only in Sézary that is a small sub group of the CTCL, but maximize the value of the drug in the whole of CTCL together, of course, with mycosis fungoides. And of course, the other option of asking for accelerated approval still remains. And as you know, in order to get accelerated approval anyway, we need 12 months durability of response that is needed for this. And of course, we need to align on what the registrational trial could look like.

Arthur He: Just quick on the ANKET program. It’s great to see the progress along and the expanding of the portfolio. Specifically on the 6501, I’m just curious for the trial, you’re going to evaluate initially. Would — is there CD20 color for the patient inclusion? And how about the dosing strategy there, if you can give additional color. Appreciate it.

Sonia Quaratino: Sure. In the study are going to be recruited, the CD20 positive non-Hodgkin lymphoma. Again, in every subtype. And this is a classic first human trial. And therefore, we are the first cohort, as you can imagine, as the first patient was enrolled in March. It’s a dose escalation study with expansion.

Arthur He: And how about the dosing wise? What’s the dosing interval and the strategy for the dosing escalation?

Sonia Quaratino: Well, the dose escalation is guided by the safety signals that we see and, of course, by statistical consideration and appetite of the investigators depending on the safety and the exposure that we observed at each cohort.

Operator: We have no further phone questions at this time. I would now like to turn the call back to Mr. Herve Brailly for any closing remarks.

Herve Brailly: Yes. Thanks a lot for your questions. And we’re looking forward to the next meeting and the next important steps will be the presentation. The overall presentation at the ACR to present the features of ADC, OCD, the IPH45 and then, of course, the general meeting taking place on May 21. So we’re looking forward to reconnecting with you all on those two opportunities. And I wish you a very good day, and looking forward to the next steps.

Operator: Ladies and gentlemen, this concludes today’s call, and we thank you for your participation. You may now disconnect.